Dr.Brian Kirk

Brian A. Kirk, Ph.D. has been employed in both the biotech and pharmaceutical industries for over 20 years.  He has a wealth of experience, working in the areas of synthetic organic, polymer, combinatorial and medicinal chemistries.  He spearheaded the drug discovery efforts for multiple clinical candidates and successfully facilitated the tech transfer of the manufacturing processes from the bench into the pilot plant.  He is highly knowledgeable in the areas of metabolic disease, oncology and cardiovascular disease, but has worked on numerous therapeutic targets during his tenure in industry.

Brian began his career at Pharmacopeia, where he designed and synthesized combinatorial libraries for numerous large pharma clients.  He then went to work in the medicinal chemistry department at Merck Research Laboratories, holding positions of increasing responsibility during his tenure there.  While at Merck, Brian served on the project team that developed Januvia, a drug NDA-approved for treatment of type 2 diabetes.  After Merck, he then made the jump to the biotech industry in Boston, working in the chemistry department at Surface Logix.  There, Brian held positions of increasing responsibility, eventually providing oversight of many discovery research efforts as well as GMP manufacturing campaigns for several clinical candidates.  Most recently, Brian has been working as an independent consultant, heavily involved in compliance auditing for bioanalytical method validation and toxicology reports for small molecule clinical candidates.